BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Pharma Research

China's 2026 Reimbursement Lists: 10 Drugs That Will Show Where Beijing Is Paying, and the Commercial List's Second Year

Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...

November 02, 2026 | Regulatory

Alkermes Advances Orexin-Based Depression Treatment into Phase II Clinical Trial

Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants ...

November 02, 2026 | News

Immunome’s Varegacestat Moves into European Regulatory Review Following Positive Phase III Results

The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements ac...

November 02, 2026 | News

Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...

October 30, 2026 | News

MEPSGEN Launches NanoCalibur Mini to Accelerate Nanoparticle Formulation for Drug Discovery

Automated system enables rapid, reproducible formulation screening with minimal sample consumption Completes the NanoCalibur® Series (Mini, Lab, Pro...

October 28, 2026 | News

Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy

GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to...

October 27, 2026 | News

Insilico Medicine Hits First AI-Driven Oncology Milestone in $888 Million Servier Collaboration

Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. Insilico reach...

October 22, 2026 | News

The PD-(L)1 x VEGF Bispecific Race: Every APAC Programme in the Clinic, Counted

When the ESMO Congress opens in Madrid on 23 October, one drug class will be hard to miss. Two days in, on the evening of Sunday 25 October, the Presidenti...

October 16, 2026 | Analysis

Mitochondrial-Derived Peptides: What Research Has Shown So Far

Scientists have described eight MDPs: humanin, MOTS-c and six small humanin-like peptides (SHLP1 to SHLP6). Research has focused on different aspects of th...

October 12, 2026 | News

Asieris Pharmaceuticals and Theramex Sign Over $250 Million Licensing Deal for Cervical Precancer Therapy CEVIRA

Agreement is expected to grant Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for th...

October 13, 2026 | News

Caliway’s CBL-514 Hits Phase II Pain-Reduction Endpoint in Dercum’s Disease

Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations...

September 23, 2026 | News

Waters Launches BD FACSDiscover A7 Cell Analyzer to Expand Access to Advanced Flow Cytometry

Waters Corporation announced the global commercial launch of the BD FACSDiscover™ A7 Cell Analyzer, which uniquely combines exceptional spectra...

September 17, 2026 | News

Ecolab Life Sciences Opens New Resin Manufacturing Facility in China

Demand for advanced purification solutions is growing as industries look to improve performance while using less water and fewer natural resources. Industr...

September 16, 2026 | News

Exegenesis Bio, Modalis Partner to Advance CRISPR-Based DMD Therapy MDL-201

Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883; "Modalis") announced that they have signed a research collaboration and license agr...

September 14, 2026 | News

Stay Connected